Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 19;12:746594. doi: 10.3389/fphar.2021.746594

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Li, Yi, Liu, Jiang, Pan, Yang, Liu, Liu and Wang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Human DPP-4 occupancy by saxagliptin and M2 following coadministration of inhibitors or inducers. (A) Human DPP-4 by saxagliptin of 5 mg (∩) and 2.5 mg (∩) with ketoconazole (200 mg, twice daily). (B) Human DPP-4 by saxagliptin of 5 mg (∩) with delavirdine (400°mg, twice daily). (C) Human DPP-4 by saxagliptin of 5 mg (∩) with rifampicin (600°mg, once daily). The black lines (∩) represent human DPP-4 by saxagliptin of 5 mg without inhibitors/inducers. The blue squares (□) and blue up-triangles (△) refer to observed DPP-4 occupancy data of saxagliptin and M2 without inhibitors/inducers and observed DPP-4 occupancy data of saxagliptin and M2 with rifampicin on the sixth day, respectively.